DE69300945T2 - Fettstoffwechsel verbessernde Zusammensetzung. - Google Patents

Fettstoffwechsel verbessernde Zusammensetzung.

Info

Publication number
DE69300945T2
DE69300945T2 DE69300945T DE69300945T DE69300945T2 DE 69300945 T2 DE69300945 T2 DE 69300945T2 DE 69300945 T DE69300945 T DE 69300945T DE 69300945 T DE69300945 T DE 69300945T DE 69300945 T2 DE69300945 T2 DE 69300945T2
Authority
DE
Germany
Prior art keywords
compound
group
glutathione
diseases
dicarboxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69300945T
Other languages
German (de)
English (en)
Other versions
DE69300945D1 (de
Inventor
Yuuichi Isowaki
Kazumi Ogata
Shinji Ohmori
Takahiro Sakaue
Hideki Tsuruoka
Yasuko Umegaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69300945D1 publication Critical patent/DE69300945D1/de
Publication of DE69300945T2 publication Critical patent/DE69300945T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69300945T 1992-07-17 1993-07-15 Fettstoffwechsel verbessernde Zusammensetzung. Expired - Fee Related DE69300945T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19074892 1992-07-17

Publications (2)

Publication Number Publication Date
DE69300945D1 DE69300945D1 (de) 1996-01-18
DE69300945T2 true DE69300945T2 (de) 1996-04-25

Family

ID=16263093

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69300945T Expired - Fee Related DE69300945T2 (de) 1992-07-17 1993-07-15 Fettstoffwechsel verbessernde Zusammensetzung.

Country Status (11)

Country Link
US (1) US5378692A (enExample)
EP (1) EP0579222B1 (enExample)
JP (1) JPH0680582A (enExample)
KR (1) KR100205264B1 (enExample)
AT (1) ATE131046T1 (enExample)
CA (1) CA2099346A1 (enExample)
DE (1) DE69300945T2 (enExample)
DK (1) DK0579222T3 (enExample)
ES (1) ES2080564T3 (enExample)
GR (1) GR3018325T3 (enExample)
TW (1) TW225992B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0469156B1 (en) * 1990-02-17 1996-10-23 Senju Pharmaceutical Co., Ltd. Glutathione derivative
TW252918B (enExample) * 1993-03-31 1995-08-01 Senju Pharma Co
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
DE102005022845A1 (de) * 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
JP5356174B2 (ja) * 2009-10-02 2013-12-04 日本メナード化粧品株式会社 Ｓ−ラクトイルグルタチオン及び／又はその塩を含有することを特徴とする医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2187327B1 (enExample) * 1972-06-15 1975-06-20 Rech Pharm Scientifiques
DE3722647A1 (de) * 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger Galenische verwendung eines tripeptids als arzneimittel
JPH02255624A (ja) * 1989-03-29 1990-10-16 Senjiyu Seiyaku Kk 血小板凝集抑制剤
JP2815179B2 (ja) * 1989-07-14 1998-10-27 千寿製薬株式会社 抗炎症および／または抗アレルギー剤
JP2919870B2 (ja) * 1989-09-29 1999-07-19 千寿製薬株式会社 肝障害抑制剤
EP0469156B1 (en) * 1990-02-17 1996-10-23 Senju Pharmaceutical Co., Ltd. Glutathione derivative
WO1991015204A2 (en) * 1990-04-09 1991-10-17 The Rockefeller University METHOD AND AGENTS FOR THE SELECTIVE REDUCTION OF Lp(a)
DE69123428T2 (de) * 1990-04-26 1997-05-15 Senju Pharma Co Inhibitor von lebererkrankungen
US5212159A (en) * 1991-02-27 1993-05-18 Senju Pharmaceutical Co., Ltd. Anticataract composition

Also Published As

Publication number Publication date
ATE131046T1 (de) 1995-12-15
KR100205264B1 (ko) 1999-07-01
KR940001901A (ko) 1994-02-16
EP0579222A2 (en) 1994-01-19
TW225992B (enExample) 1994-07-01
EP0579222B1 (en) 1995-12-06
DK0579222T3 (da) 1996-04-09
GR3018325T3 (en) 1996-03-31
ES2080564T3 (es) 1996-02-01
DE69300945D1 (de) 1996-01-18
CA2099346A1 (en) 1994-01-18
EP0579222A3 (en) 1994-05-18
US5378692A (en) 1995-01-03
JPH0680582A (ja) 1994-03-22

Similar Documents

Publication Publication Date Title
DE69400382T2 (de) Zusammensetzung zur Förderung des Lipidmetabolismus
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
DE69805334T2 (de) Derivate des vitamin e
DE3429551C2 (enExample)
DE69001722T2 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
DE3907688C2 (de) Salze von ungesättigten Fettsäuren mit Aminosäuren, Verfahren zu ihrer Herstellung sowie die Verwendung der ersteren und von weiteren derartigen Salzen
DE2947624A1 (de) Beta, gamma -dihydropolyprenylalkohol und diesen enthaltendes blutdrucksenkendes arzneimittel
DE69226487T2 (de) Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
DE60313886T2 (de) Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Behandlung von Obesitas
EP0038343A1 (de) Substituierte oxocarbonsäuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel.
DE3643119A1 (de) Therapeutische zusammensetzung fuer diabetes-komplikationen
DE69626118T2 (de) Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen
DE69001004T2 (de) Zusammensetzung gegen leberkrankheiten.
CH621334A5 (enExample)
DE3875324T2 (de) Dl-5-((2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidin-2,4-dion als antiatherosklerosemittel.
DE60217369T2 (de) Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
DE69202594T2 (de) Zusammensetzung gegen Katarakt.
DE69209115T2 (de) Sauerstoffradikalfänger
US5378692A (en) Method of lowering lipids
DE69600714T2 (de) Antiallergische Zusammensetzung enthaltend eine Phosphorsäurediester-Verbindung
DE1804448C3 (de) β-(2-p-Chlorphenyl-thiazol-4-yl)-acrylsäure, pharmazeutisch verträgliche Salze davon und Verfahren zur Herstellung der Verbindung
DE2520483A1 (de) Phenoxy-isobuttersaeurederivate und diese verbindungen enthaltende arzneimittel
DE2351292B2 (de) 2,10-Dichlor-6-äthoxycarbonyl-12- methyl-12Hdibenzo [d,g] [13] dioxocin und Verfahren zu dessen Herstellung sowie diese Verbindung enthaltende Arzneimittel
DE68910021T2 (de) Oxaminsäureverbindungen und pharmazeutische Zusammensetzungen zur Anwendung bei der Verbesserung geschädigter Hirnfunktionen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee